BRCA1 and ovarian carcinoma: This very recent milestone of biomarker-guided, first-line PARPi treatment has been based on the knowledge that ovarian cancer with BRCA1/2 mutations comprises a molecular Achilles’ Heel that can be exploited by targeting HRD (9).